How CAR T-Cell Therapy Measures Up in Follicular Lymphoma
In relapsed or refractory follicular lymphoma, treatment with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel, Yescarta) was associated with better outcomes compared with currently available therapies, a comparative analysis of the ZUMA-5 and SCHOLAR-5 trials suggested. Overall response rate (ORR) was higher, and both progression-free survival (PFS) and overall survival (OS) were […]